| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Original Research |
1 Department of Radiology, University of Michigan, 1500 E Medical Center Dr.,
Ann Arbor, MI 48109-0030.
2 School of Public Health, University of Michigan, Ann Arbor, MI.
3 Department of Neurology, University of Michigan, Ann Arbor, MI.
OBJECTIVE. The purpose of our study was to explore the feasibility and utility of 2D chemical shift imaging (CSI) MR spectroscopy in the evaluation of new areas of contrast enhancement at the site of a previously treated brain neoplasm.
MATERIALS AND METHODS. Two-dimensional CSI (point-resolved spectroscopy sequence [PRESS]; TR/TE, 1,500/144) was performed in 29 consecutive patients (4-54 years old; mean age, 34 years) who had a new contrast-enhancing lesion in the vicinity of a previously diagnosed and treated brain neoplasm. Clinical and imaging follow-up, and histopathology in 16 patients, were used as indicators of the identity of a lesion.
RESULTS. Diagnostic-quality spectra were obtained in 97% of the patients. The Cho/Cr (choline/creatine) and Cho/NAA (choline/N-acetyl aspartate) ratios were significantly higher, and the NAA/Cr ratios significantly lower, in tumor than in radiation injury (all three differences, p < 0.0001). The Cho/Cr and Cho/NAA ratios were significantly higher in radiation injury than in normal-appearing white matter (p < 0.0003 and p < 0.0001, respectively), whereas NAA/Cr ratios were not different (p = 0.075). Mean Cho/Cr ratios were 2.52 for tumor, 1.57 for radiation injury, and 1.14 for normal-appearing white matter. Mean Cho/NAA ratios were 3.48, 1.31, 0.79, and mean NAA/Cr ratios were 0.79, 1.22, and 1.38, respectively. When values greater than 1.8 for either Cho/Cr or Cho/NAA ratios were considered evidence of tumor, 27 of 28 patients could be correctly classified.
CONCLUSION. Two-dimensional CSI MR spectroscopy can differentiate tumor from radiation injury in patients with recurrent contrast-enhancing intracranial lesions. In these lesions, the Cho/NAA and Cho/Cr ratios may be the best numeric discriminators.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  R. F. Barajas Jr, J. S. Chang, M. R. Segal, A. T. Parsa, M. W. McDermott, M. S. Berger, and S. Cha Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Radiology, November 1, 2009; 253(2): 486 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.C. Sundgren MR Spectroscopy in Radiation Injury AJNR Am. J. Neuroradiol., September 1, 2009; 30(8): 1469 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Gasparetto, M. A. Pawlak, S. H. Patel, J. Huse, J. H. Woo, J. Krejza, M. R. Rosenfeld, D. M. O'Rourke, R. Lustig, E. R. Melhem, et al. Posttreatment Recurrence of Malignant Brain Neoplasm: Accuracy of Relative Cerebral Blood Volume Fraction in Discriminating Low from High Malignant Histologic Volume Fraction Radiology, March 1, 2009; 250(3): 887 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Smith, R. C. Carlos, L. R. Junck, C. I. Tsien, A. Elias, and P. C. Sundgren Developing a Clinical Decision Model: MR Spectroscopy to Differentiate Between Recurrent Tumor and Radiation Change in Patients with New Contrast-Enhancing Lesions Am. J. Roentgenol., February 1, 2009; 192(2): W45 - W52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Petrou, R.E. Harris, B.R. Foerster, S.A. Mclean, A. Sen, D.J. Clauw, and P.C. Sundgren Proton MR Spectroscopy in the Evaluation of Cerebral Metabolism in Patients with Fibromyalgia: Comparison with Healthy Controls and Correlation with Symptom Severity AJNR Am. J. Neuroradiol., May 1, 2008; 29(5): 913 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Brandes, A. Tosoni, F. Spagnolli, G. Frezza, M. Leonardi, F. Calbucci, and E. Franceschi Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology Neuro-oncol, January 1, 2008; 10(3): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Cao, P. C. Sundgren, C. I. Tsien, T. T. Chenevert, and L. Junck Physiologic and Metabolic Magnetic Resonance Imaging in Gliomas J. Clin. Oncol., March 10, 2006; 24(8): 1228 - 1235. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
